Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Procholecystokinin expression and processing in cardiac myocytes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) potentiate glucose-induced insulin secretion and are therefore thought to be responsible for the incretin effect. The magnitude of the incretin effect, defined as the fraction of postprandial insulin secretion stimulated by intestinal factors, has been reported to be up to ∼60% in healthy individuals. In several pathological conditions but especially in patients with type 2 diabetes, the incretin effect is severely reduced or even absent. In line with this, the insulinotropic effects of GIP and GLP-1 are impaired in patients with type 2 diabetes, even when administered in supraphysiological doses. In healthy individuals, GIP has been proposed to be the most important incretin hormone of the two, but the individual contribution of the two is difficult to determine. However, using incretin hormone receptor antagonists: the novel GIP receptor antagonist GIP(3-30)NH2 and the widely used GLP-1 receptor antagonist exendin(9-39)NH2, we can now distinguish between the effects of the two hormones. In this review, we present and discuss studies in which the individual contribution of GIP and GLP-1 to the incretin effect in healthy individuals have been estimated and discuss the limitations of using incretin hormone receptor antagonists.

OriginalsprogEngelsk
TidsskriftPeptides
ISSN0196-9781
DOI
StatusE-pub ahead of print - 3 nov. 2019

Bibliografisk note

Copyright © 2019. Published by Elsevier Inc.

ID: 58310958